Palvella Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$158.25

−2.48%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: $166.73
Previous close: $162.28
Volume: 112,448
Day's high: $166.73
Day's low: $157.83

In brief

Palvella Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $2.28B.
Its shares closed at $162.28 on 4 Nov 2026, up 116.2% over the past year.
From India you can buy PVLA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Palvella Therapeutics, Inc. (PVLA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PVLA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PVLA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Set a 52-week high on 4 Nov 2026
Closed at $162.28 on 4 Nov 2026: 0.9% below the 52-week high of $163.75 (4 Nov 2026) and 124.7% above the low of $72.23 (30 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +26.8% (SPY −1.6%, XLV +13.5%). 3 months: +4.8% (SPY −0.4%, XLV +15.5%). 1 year: +116.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PVLA, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $162.28 was 14.3% above its 50-day average ($141.98) and 27.0% above its 200-day average ($127.73). It has closed above the 200-day for 8 sessions, since 26 Oct 2026.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
9.8 days to cover short interest
2.4M shares were sold short at the 15 Oct 2026 settlement; covering them would take 9.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 1.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 407.1K shares was 1.7× the average of the 30 sessions before it (238.1K), as the price rose 6.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+26.8%

6 months+24.7%

1 year+116.2%

5 years—

Newswire

About

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Website

Notable moves

July 20, 2026
−21.04%
February 24, 2026
+37.08%
February 13, 2025
+18.48%

Palvella Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$158.25

−2.48%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: $166.73
Previous close: $162.28
Volume: 112,448
Day's high: $166.73
Day's low: $157.83

In brief

Palvella Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $2.28B.
Its shares closed at $162.28 on 4 Nov 2026, up 116.2% over the past year.
From India you can buy PVLA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Palvella Therapeutics, Inc. (PVLA) shares from India?

Do I need the price of a whole PVLA share to invest?

How much can I invest in US stocks in a year?

Can I trade PVLA options or futures?

Insights

Quotes run fifteen minutes behind.

Set a 52-week high on 4 Nov 2026
Closed at $162.28 on 4 Nov 2026: 0.9% below the 52-week high of $163.75 (4 Nov 2026) and 124.7% above the low of $72.23 (30 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY and its sector fund XLV over 1 year
1 month: +26.8% (SPY −1.6%, XLV +13.5%). 3 months: +4.8% (SPY −0.4%, XLV +15.5%). 1 year: +116.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PVLA, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $162.28 was 14.3% above its 50-day average ($141.98) and 27.0% above its 200-day average ($127.73). It has closed above the 200-day for 8 sessions, since 26 Oct 2026.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
9.8 days to cover short interest
2.4M shares were sold short at the 15 Oct 2026 settlement; covering them would take 9.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 1.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 407.1K shares was 1.7× the average of the 30 sessions before it (238.1K), as the price rose 6.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+26.8%

6 months+24.7%

1 year+116.2%

5 years—

Newswire

About

Website

Notable moves

July 20, 2026
−21.04%
February 24, 2026
+37.08%
February 13, 2025
+18.48%

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. in brief

Set a 52-week high on 4 Nov 2026

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

9.8 days to cover short interest

Volume 1.7× its 30-session average on 4 Nov 2026

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. in brief

Set a 52-week high on 4 Nov 2026

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

9.8 days to cover short interest

Volume 1.7× its 30-session average on 4 Nov 2026